Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Jono, T.
Right arrow Articles by Horiuchi, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jono, T.
Right arrow Articles by Horiuchi, S.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

J. Biochem, 2004, Vol. 136, No. 3 351-358
© 2004 The Japanese Biochemical Society


BIOCHEMISTRY

N{varepsilon}-(Carboxymethyl)lysine and 3-DG-Imidazolone Are Major AGE Structures in Protein Modification by 3-Deoxyglucosone

Tadashi Jono1,2,*, Ryoji Nagai1,*, Xia Lin1, Naila Ahmed3, Paul J. Thornalley3, Motohiro Takeya4 and Seikoh Horiuchi1,§

1 Department of Medical Biochemistry, 2 Department of Psychiatry, and 4 Department of Cell Pathology, Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University, Kumamoto, 860-0811; and 3 Department of Biological Sciences, University of Essex, Colchester, UK

The levels of plasma 3-deoxyglucosone (3-DG) increase under hyperglycemic conditions and are associated with the pathogenesis of diabetic complications because of the high reactivity of 3-DG with proteins to form advanced glycation end products (AGE). To investigate potential markers for 3-DG–mediated protein modification in vitro and in vivo, we compared the yield of several 3-DG–derived AGE structures by immunochemical analysis and HPLC and measured their localization in human atherosclerotic lesions. When BSA was incubated with 3-DG at 37°C for up to 4 wk, the amounts of N{varepsilon}-(carboxymethyl)lysine (CML) and 3-DG-imidazolone steeply increased with incubation time, whereas the levels of pyrraline and pentosidine increased slightly by day 28. In contrast, significants amount of pyrraline and pentosidine were also observed when BSA was incubated with 3-DG at 60°C to enhance AGE-formation. In atherosclerotic lesions, CML and 3-DG-imidazolone were found intracellularly in the cytoplasm of most foam cells and extracellularly in the atheromatous core. A weak-positive immunoreaction with pyrraline was found in the extracellular matrix and a few foam cells in aortic intima with atherosclerotic lesions. Our results provide the first evidence that CML and 3-DG-imidazolone are major AGE structures in 3-DG–modified proteins, and that 3-DG-imidazolone provides a better marker for protein modification by 3-DG than pyrraline.

* These authors contributed equally to the present work.

§ To whom correspondence should be addressed. Tel/Fax: +81-96-364-6940, E-mail: horiuchi{at}gpo.kumamoto-u.ac.jp


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J BiochemHome page
H. Sakiyama, M. Takahashi, T. Yamamoto, T. Teshima, S. H. Lee, Y. Miyamoto, Y. Misonou, and N. Taniguchi
The Internalization and Metabolism of 3-Deoxyglucosone in Human Umbilical Vein Endothelial Cells
J. Biochem., February 1, 2006; 139(2): 245 - 253.
[Abstract] [Full Text] [PDF]


Home page
J BiochemHome page
W. Koito, T. Araki, S. Horiuchi, and R. Nagai
Conventional Antibody against N{varepsilon}-(Carboxymethyl)Lysine (CML) Shows Cross-Reaction to N{varepsilon}-(Carboxyethyl)Lysine (CEL): Immunochemical Quantification of CML with a Specific Antibody
J. Biochem., December 1, 2004; 136(6): 831 - 837.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.